***N*-(3-Chloro-2-methylphenyl)-3-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-a]pyrazine-5-carboxamide, OSM-S-255**



Representative Example: http://malaria.ourexperiment.org/uri/64b

Prepared according to General Procedure **F** from: **OSM-S-XXX** (150 mg, 0.38 mmol) to give the title compound as a tan powder (86 mg, 58%); **m.p.** 220–221 ˚C; **IR** νmax (film) /cm-1 3230, 2832, 1686, 1612, 1461, 1254; **1H NMR** (400 MHz, DMSO-d*6*) δ: 10.62 (1H, s), 9.63 (1H, s), 8.34 (1H, s), 7.57 (2H, dapp, *J* 8.7), 7.32 (1H, d, *J* 7.6), 7.16 (1H, t, *J* 8.0), 7.02 (2H, dapp, *J* 8.7), 7.01 (1H, d, *J* 7.6), 3.77 (3H, s), 2.22 (3H, s); **13C NMR** (100 MHz, DMSO-d*6*) δ: 160.61, 158.07, 147.60, 146.10, 145.76, 132.20, 133.80, 130.44, 130.30, 129.84 (2 C), 126.88, 126.76, 124.59, 123.95, 119.54, 114.08 (2 C), 55.36, 15.04; **m/z** (ESI+) 394 [M+H]+; **HRMS** (APCI+) found 394.10644 [M+H]+, C20H17ClN5O2 requires 394.10653.

*O=C(C1=CN=CC2=NN=C(C3=CC=C(OC)C=C3)N21)NC4=CC=CC(Cl)=C4C*

*InChI=1S/C20H16ClN5O2/c1-12-15(21)4-3-5-16(12)23-20(27)17-10-22-11-18-24-25-19(26(17)18)13-6-8-14(28-2)9-7-13/h3-11H,1-2H3,(H,23,27)*